| Date | Title | Description |
| 04.11.2025 | LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction | BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufactu... |
| 22.10.2025 | VitriVax Raises $17.25M in Series B Financing | VitriVax, Inc., a Boulder, CO-based vaccine formulation technology company, raised a total of $17.25m in Series B financing.
The round was co-led by Adjuvant Capital and RA Capital Management-.
The company intends to use the proceeds from t... |
| 22.10.2025 | VitriVax: $17.25 Million Series B Closed To Advance Thermostable Single-Shot Vaccine Platform | VitriVax, a biotechnology company developing next-generation vaccine formulation technologies, announced it has raised $17.25 million in Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management, LP, with procee... |
| 01.08.2025 | Nigerian court blocks sale of 54gene’s assets, as founder claims investor wrongdoing | A Federal High Court in Lagos has granted an injunction blocking the sale of 54gene’s assets, preventing the dissolution of what was once one of Africa’s most promising startups, according to court documents seen by TechCabal. Assets slated... |
| 18.03.2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| 18.03.2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| 17.03.2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding.
The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| 02.02.2024 | New investment brings LimmaTech’s series A to CHF 40 million |
Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate or excessive use of antibiotics has resulted in a major increase in bacterial resistance against the formerly effective drugs. LimmaTech aim... |
| 02.11.2023 | Memo Therapeutics Raises CHF 25 Million Series C Financing | |
| 10.10.2023 | Swiss-based LimmaTech Biologics raises €35M to combat emerging antimicrobial resistance | Read this article in:
Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical company, announced on Monday, October 9, that it has secured $37M (approximately €35M) in a Series A round of funding.
The investment was co-led b... |
| 09.10.2023 | First equity funding for LimmaTech Biologics | |
| 16.02.2022 | Memo Therapeutics raises CHF 23 million | |
| 16.09.2021 | 54gene Closes $25M Series B to Advance Global Drug Discovery Capabilities | |
| 07.07.2021 | VitriVax Announces Series A Financing to Further Demonstrate Feasibility of its Thermostable, Single-Dose Vaccine Technology, Aiming to Make Life-Saving Biologics Widely Accessible to Underserved Popu... | |
| 27.05.2021 | IP GROUP PLC
IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 27.05.2021 | IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 04.05.2021 | US life science investment firm establishes European presence in Zurich | Launched in 2019, Adjuvant's debut fund will support promising new technologies for indications that the venture capital industry has largely ignored. To finance these ambitious goals, Adjuvant has assembled a unique coalition of convention... |
| 04.05.2021 | US life science investment firm establishes European presence in Zurich | |
| 29.04.2021 | Philippe Dro Joins Adjuvant Capital as Partner | |
| 18.02.2021 | Adjuvant Capital Closes $300M Venture Fund | Adjuvant Capital, a NYC-based global global life sciences venture capital firm, closed its first fund, at $300m.
Backers included the Bill & Melinda Gates Foundation, Anthos Fund & Asset Management, Beacon Pointe Advisors, CDC Group... |
| 18.02.2021 | Adjuvant Capital Closes $300M Venture Fund | Adjuvant Capital, a NYC-based global global life sciences venture capital firm, closed its first fund, at $300m. Glenn Rockman and Jenny Yip, managing partners at Adjuvant Capital
Backers included the Bill & Melinda Gates Foundation, An... |
| 18.02.2021 | New $300 Million Venture Fund Spotlights Role Of Women In Venture Capital And Public Health | A U.S.-based venture capital firm, Adjuvant Capital, has just announced a new $300 million fund, counting the Bill & Melinda Gates Foundation among its investors. The fund is focused on accelerating the development of medical innovation... |
| 18.02.2021 | Adjuvant Capital Closes $300M Venture Fund | Adjuvant Capital, a NYC-based global global life sciences venture capital firm, closed its first fund, at $300m.
Backers included the Bill & Melinda Gates Foundation, Anthos Fund & Asset Management, Beacon Pointe Advisors, CDC Group... |
| 18.02.2021 | Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health | NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Adjuvant Capital today announced an oversubscribed $300 million fund focused on accelerating the development of medical innovations for historically overlooked public health challenges. Launched in 20... |
| 18.02.2021 | Adjuvant Capital Raises $300 Million Global-Health Venture Fund | Investors including the Bill & Melinda Gates Foundation have backed a $300 million venture-capital fund seeking to make medical innovations more accessible to people in developing countries.
The Gates Foundation has committed $75 millio... |
| 18.02.2021 | Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health | Merck, Novartis, IFC, Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Dalio Philanthropies, Doris Duke Charitable Foundation, ELMA Investments Ltd., Ford Foundation, MacArthur Foundation, Global Health Investment... |
| 18.02.2021 | Gates, Merck and Novartis-backed Adjuvant Capital raises $300M for neglected diseases | A major group of pharma and charitable groups have joined forces to raise a $300 million venture round for Adjuvant Capital as it goes after forgotten diseases across the globe.
Those big names include Merck, Novartis, IFC, the Bill & M... |
| 18.02.2021 | Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health | |
| 18.02.2021 | Gates, Merck and Novartis-backed Adjuvant Capital raises $300M for neglected diseases | A major group of pharma and charitable groups have joined forces to raise a $300 million venture round for Adjuvant Capital as it goes after forgotten diseases across the globe.
Sponsored By: IsoPlexis
Multi-Omic Approaches Reveal Functiona... |
| 03.02.2021 | Frontier Nutrition Raises $6 Million Series B Financing led by Adjuvant Capital | Frontier Nutrition, a company manufacturing and marketing affordable fortified snacks in Bangladesh, has announced a $6 million Series B financing led by Adjuvant Capital, a life sciences fund backed by the Bill & Melinda Gates Foundati... |
| 22.01.2021 | 54gene unveils scientific research laboratory in Nigeria | Share this:
Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new... |
| 28.10.2020 | African genomics venture 54gene launches clinical research program in Nigeria | Share this:
Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new... |
| 02.08.2020 | How To Start A VC: Interview With Maya Horgan Famodu, Founder, Ingressive Capital | “I have an obligation to use my access to empower the next generation of |
| 19.05.2020 | ChromaCode’s tech to boost COVID-19 testing gets Bill Gates’s backing | Boasting a technology that can dramatically increase the capacity of existing polymerase chain reaction (PCR) testing used to identify people infected with COVID-19 and other illnesses, ChromaCode has attracted new funding from Bill Gates-b... |
| 14.04.2020 | Nigerian healthtech 54gene closes $15m Series-A raise | Nigerian healthtech platform 54gene has closed a $15-million Series-A round.
The round was led by Adjuvant Capital, a US based life sciences fund. Adjuvant Capital’s investor’s include the World Bank’s International Finance Corporation (IF... |
| 14.04.2020 | To accelerate innovation, the CDC should ease limits on which labs can handle the coronavirus | Not long after SARS-CoV-2 was first identified in December 2019 as the cause of an alarming cluster of severe pneumonia cases in central China, the U.S. Centers for Disease Control and Prevention correctly advised that the virus should be i... |
| 14.04.2020 | 54gene Closes $15M Series A | 54gene, the African genomics research, services, and development company has closed a Series A round of $15M, led by Adjuvant Capital, a life sciences fund backed by the International Finance Corporation, Novartis, and the Bill & Melind... |
| 14.04.2020 | Nigerian healthtech 54gene closes $15m Series-A raise | Nigerian healthtech platform 54gene has closed a $15-million Series-A round.
The round was led by Adjuvant Capital, a US based life sciences fund. Adjuvant Capital’s investor’s include the World Bank’s International Finance Corporation (IFC... |
| 14.04.2020 | 54Gene closes $15 million Series A round to scale its African DNA research operations | Nigerian health company 54Gene has closed a $15 million round to scale its genome data bank operations and research collaboration efforts in Africa.
The round was led by Adjuvant Capital, a US firm whose fund focuses on investing in compani... |
| 14.04.2020 | 54gene raises $15M Series A to accelerate African genetics research | Share this:
Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new... |
